Do You Read All Of Our Blogs?
This page you have reached is an archive of old blog posting. Just follow the links below to go to the main blog pages to read the latest blog posting.
Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.
I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog:
Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog:
Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog:
Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog:
Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog
and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
Heart watch blog:
About 13 million Americans suffer from coronary artery disease. Coronary artery disease is the leading cause of death in American men and women amounting a staggering 20 percent of all causes of death. The tremendous responsibility of running a heart blog is entrusted to Daniel. He is creating blog posts with the help and support of other bloggers.
Oct 11, 2005
Comedian Louis Nye Dies of Lung Cancer
The man who brought us the phrase "Hi Ho, Steverino" has died of lung cancer. Louis Nye died over the weekend of lung cancer at age 92.
Louis Nye is one of America's most popular actor and comedians. He came into prominence on the long running Steve Allen Show where his "HI-HO STEVERINO" became a household phrase. Daily Variety described him as,.... "One of the finest actor/comics who turns himself into many characters who are vastly entertaining."
Louis has appeared in every area of show business including radio, Broadway, movies with Jack Lemon, James Garner, Lucille Ball and Robert Mitchum.... The Lecture Circuit, Concerts, Night Clubs And Television. He has starred on TV with Judy Garland, Jack Benny, Bob Hope, Jimmy Durante, Jackie Gleason, Dolly Parton, Steve Martin, Bill Cosby, Jonathan Winters.... Appearances on Love Boat, as the memorable Sonny Drysdale on The Beverly Hillbillies, The Munsters, St. Elsewhere,....the list goes on and on.
Oct 6, 2005
Alcohol-lung cancer link is weak
Doctors often suggest that alcohol use in addition to smoking is an additional risk factor for lung cancer. Pooled data from seven studies on diet and cancer conducted by Dr. Jo L. Freudenheim from the State University of New York at Buffalo and colleagues suggests only weak link between alcohol consumption and development of lung cancer as this data is mainly confined to men who never smoked.
Smoking is an established risk factor for the development of lung cancer, however various factors that lead to lung cancer in non-smokers are not well defined. The researchers note that mortality due to lung cancer is high in studies of alcoholics, "but the greater risk may be explained, in part or entirely, by the fact that the people in these populations were also more likely to smoke."
Freudenheim and colleagues tried to separate the effect of smoking from that of alcohol on lung cancer risk in an analysis of 399,767 study participants and found that 3137 lung cancer cases revealed a "slightly greater" overall risk for lung cancer in men and women consuming two drinks or more per day (30 grams or more per day) compared with no alcohol consumption. The risk was increased 21 percent for men and 16 percent for women.
Among men who never smoked, consumption of 15 grams or more of alcohol per day was association with a 6-fold increased risk of developing lung cancer.
This finding is "notable," the authors write, "although the absolute risk of lung cancer in this group is, of course, small."
Oct 3, 2005
Novel imaging program for identifying Lung Cancer
Early detection of lung cancer is very important as it may make a difference of life and death for you. The good news is that the researchers are developing newer and newer techniques to detect lung cancer early.
CeMines, Inc. announced that it has entered into a clinical research and product distribution agreement with Denver-based Colorado Heart and Body Imaging, LLC (CHBI), a recognized leader in the early detection of cancer, heart disease and osteoporosis. The agreement provides CHBI the opportunity to use CeMines' CellCorrectTMLAb Detection Test Kitsin upcoming clinical studies that relate patient serum biomarkers and imaging in diverse and healthy population groups.
The CeMines CellCorrectTMLAbkit detects altered autoimmunity and associated patterns (CeMines Molecular FingerPrintingTM) of lung cancer-related autoantibodies present in the bloodstream.
Roger Attick, CEO of CeMines has stated that the alliance between CeMines and CHBI has the potential to create a 'best in class' diagnostic protocol.
James Ehrlich, M.D., medical director and founder of Colorado Heart and body Imaging has reported that they were proud to add the CellCorrectLAb test to their impressive arsenal of 'best of breed' early detection technologies.
With regard to lung cancer, our nation's leading cancer killer, Ehrlich stated, "I am confident that early detection efforts, combining electron beam tomographic (EBT) imaging with CellCorrectLAbspecific serum biomarkers, should favorably change the prognosis for thousands."
Sep 30, 2005
It's never too late to quit smoking
Cigarette smoking costs about 5 million lives each year all over the world mainly due lung cancer, coronary artery disease and chronic obstructive pulmonary disease that may have resulted from smoking. Lung cancer is responsible for 28 percent of all cancer deaths in the United States. Treatment of lung cancer is progressing slowly with the introduction of newer drugs, but the best strategy would be prevention of lung cancer by avoidance or cessation of smoking.
It is never too late to stop smoking. A male who has been lifetime smoker and lives up to 75 years have 16 percent risk of developing lung cancer. However if he stops smoking at age 60 the risk would be reduced to 10 percent. If he manages to stop smoking at the age of 50 his risk would be 6 percent only. The risk would reduce further to 3 percent he quits smoking at the age of 40. Stopping at 30 years of age would decrease the risk to 1.7 percent. For non-smokers the corresponding risk would be 0.4 percent.
Sorry, I don't have the corresponding numbers for women, but I guess the numbers may be similar.
The message is, it is never too late to quit smoking.
Source: Peto R. Darby et al. Smoking cessation and lung cancer in the UK since 1950.. BMJ 2000:321:323-329
Sep 27, 2005
Eat lot of vegetables to prevent lung cancer
More evidence for the preventative role of vegetables and other food items in lung cancer! A study published in the recent issue of Journal of American Medical Association (JAMA) suggests that eating foods such as broccoli, grains and soy products may protect against lung cancer.
People who were eating food rich with the above items - such as five fruits and vegetable servings a day - had a 46% lower risk of lung cancer compared to than those whose diets contained the lowest levels of these food items, according to the study. Researchers at Houston's M.D. Anderson Cancer Center led the study.
Several studies have shown that people in Asian countries, who eat more vegetables and soy than Americans do, generally have lower cancer rates, as per the researchers. The study was conducted by surveying more than 3,400 patients with detailed questions about what they ate in the past year. About half of those questioned had lung cancer.
The following food items may confer protection against lung cancer
- Isoflavones: Soybeans and soy products such as tofu, chickpeas, red clover
- Lignans: Rye grains, linseeds, carrots, tea, spinach, broccoli and other vegetables
- Cumestrans: Beans, peas, clover, spinach and sprouts
- Phytosterols: Vegetable oils, margarines, dark breads and certain fruits and vegetables
This study is not a conclusive proof that these food items reduce the risk of lung cancer says Margaret Spitz, the study's lead investigator and chair of the center's epidemiology department. Patients may not accurately remember what they ate or how much. Spitz says she feels comfortable recommending fruits and vegetables, however, because of other strong evidence that diets centered on plant foods protect against heart disease and cancer.
Sep 25, 2005
Support Lung Cancer Alliance
Lung cancer alliance is the only national organization dedicated exclusively to advocating on behalf of the lung cancer patients and those at risk. The huge problem of lung cancer is greatly ignored and under funded despite its massive public health impact.
Services offered by the lung cancer alliance include the following:
Lung cancer hotline: toll free information and referral service for people with lung cancer and their caregivers
The phone buddy program: a peer-to-peer support network
Lung cancer awareness month: a national education and advocacy campaign
Spirit and breath: a quarterly news letter
Advocacy alert: where lung cancer advocates can receive alerts to participate or respond to important lung cancer issues.
The goal of lung cancer alliance is eradication of lung cancer and to achieve this goal the alliance work with Congress and federal agencies to make progress in lung cancer research and preventive measures.
They speak for us! Why don't we support them?
Contact information for lung cancer alliance:
888 16th Street NW
Washington DC 20006
Sep 22, 2005
New clinical trial for small cell lung cancer
Vion pharmaceuticals, Inc recently announced opening of a phase II clinical trial using its anticancer agent Choretazine in small cell lung cancer. The study is open to patients with locally advanced or metastatic small cell lung cancer whose response to the initial treatment for the disease had been poor.
In small cell lung cancer, alkylating agents have demonstrated their activity and are frequently used after cisplatin-based combinations as second-line treatment. Studies have shown Choretazine, a novel alkylating agent has a broad-spectrum anti-tumor activity in preclinical studies. The safety profile, maximum tolerated dose and schedule for Choretazine in solid tumors have been investigated by two Phase I trials. This new Phase II study in small cell lung cancer is a multi-centered that looks forward to enroll up to nearly 90 patients.
Dr. Howard Burris, investigator at the Sarah Cannon Cancer Center in Nashville, Tennessee, commented, "We are excited to be offering this promising new therapy to our patients with small cell lung cancer. Innovative therapies are needed for this difficult-to-treat patient population."
Contact info: (203) 498-4210
Sep 20, 2005
Eat vegetables to prevent lung cancer
Eat lot of vegetables to prevent lung cancer! That may be a message from the recent study conducted by researchers at Georgetown University Medical Center and the Institute for Cancer Prevention. These researchers have found that a family of compounds found in cruciferous vegetables, such as broccoli, cauliflower, and watercress, blocked lung cancer progression in both animal studies and in tests with human lung cancer cells.
The results of the study were published in September 15 issue of Cancer Research.
Researchers studied isothiocyanates, a family of such compounds, to see if it has an impact on the stages of cancer development. To test that, the researchers induced lung tumor development in experimental mice by exposing them to tobacco carcinogens, and then they fed one group of mice the veggie compounds. They found that, the use of the chemicals resulted in a reduced development of benign lung tumors to malignant tumors.
Researchers however caution that it is difficult to draw any direct comparisons between human consumption of these vegetables and the effects seen in the mice studies.
In another study the researchers looked at the effect of the same compound on human lung cancer cells, which were forced to grow quickly (as cancer does) because of insertion of a gene known to be involved in cell growth and regulation. The laboratory test showed that the derivative of isothiocyanate caused death of these fast growing cells. This study provides some insight onto "one of the possible mechanisms of action" by which the compounds may offer some protection against lung cancer development, the researchers said.
The researchers hope that, these chemicals, if put into a veggie pill of sort, might some day be used to help current and former smokers ward off development of lung cancer.
Sep 18, 2005
Tarceva benefits older lung cancer patients
New targeted lung cancer drug tarceva (erlotinib) may be especially beneficial for older lung cancer patients as per data from new research. Tarceva showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer as per researchers from Dana-Farber Cancer Institute in Boston. This is the first assessment of tarceva in patients who have not received any prior chemotherapy.
These phase II results are sufficiently promising to merit a Phase III trial comparing tarceva against standard chemotherapy as first line treatment of older patients with non-small cell lung cancer as per the researchers. Their findings will be presented at the 15th Annual Congress of the European Respiratory Society in Copenhagen, Denmark.
There were no complete responses to the drug, but 60 percent of the patients experienced either a partial response or had stable disease. Eight patients had partial responses, 33 had stable disease and 28 had progressive disease. The median survival was 46 weeks, and the median duration of partial response and stable disease was 65 weeks and 24 weeks, respectively.
"While further research is needed, our findings suggest that it may be beneficial to use erlotinib, a relatively non-toxic targeted agent, to initially treat patients with advanced lung cancer, rather than use conventional chemotherapy regimens," said Dana-Farber's Bruce Johnson, MD, who headed the research.